Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 7.25%, which has investors questioning if this is right time ...

Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. Lexicon will be responsible for ...

LXRX Boasts LX9851’s Potential in the Obesity Space Unlike the popular obesity drugs that are designed to target GLP-1 or GIPR, Lexicon is taking a novel route with its weight-loss drug.

It also makes sense, mechanistically. Novo Nordisk will likely combine Lexicon's LX9851 with Wegovy, its GLP-1-focused weight-loss drug. Lexicon stock soared 64.1%, closing at 57 cents.

Lexicon Pharmaceuticals secured a licensing deal with Novo Nordisk for LX9851, with potential payments totaling $1 billion-plus royalties. Preclinical data show that LX9851 enhances weight loss ...

THE WOODLANDS, Texas — A Houston-area pharmaceutical company has struck a billion-dollar deal with the seller of Ozempic for a potential drug also aiming to combat obesity. Lexicon ...

Lexicon Pharmaceuticals (LXRX) announced that it has entered into an exclusive license agreement with Novo Nordisk (NVO) for LX9851, a first-in-class, oral non-incretin development candidate in ...

Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week. Per the deal terms ...